Quviviq Indication
Quviviq (daridorexant) is FDA-approved for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. 1
Specific Indication Details
The FDA label is explicit and straightforward: Quviviq targets both sleep initiation problems and sleep maintenance difficulties in adults with insomnia disorder 1. This dual indication distinguishes it from some older agents that may target only one aspect of insomnia.
Key Prescribing Parameters
- Dosing: The recommended range is 25-50 mg taken orally once nightly, within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening 1
- Population: Adults only (≥18 years) 1
- Timing consideration: Avoid taking with or immediately after meals, as this delays sleep onset 1
Contraindications to Note
Quviviq is absolutely contraindicated in two specific situations 1:
- Patients with narcolepsy (orexin antagonism would worsen excessive daytime sleepiness)
- Patients with hypersensitivity to daridorexant, including those with prior angioedema with pharyngeal involvement
Clinical Context from Guidelines
While Quviviq specifically addresses insomnia disorder, the broader treatment landscape emphasizes that cognitive-behavioral therapy for insomnia (CBT-I) remains the recommended first-line intervention 2, 3. Pharmacotherapy like Quviviq is appropriately positioned for patients who have inadequate response to behavioral interventions or when combined with CBT-I 2.
The American Academy of Sleep Medicine guidelines note that newer agents targeting the orexin system represent an advancement over older benzodiazepine receptor agonists, particularly regarding concerns about long-term use and dependency 2.
Common Pitfall to Avoid
Do not prescribe Quviviq for short-term or situational insomnia—the FDA indication and supporting trials specifically address chronic insomnia disorder (symptoms present ≥3 months, ≥3 times weekly) 4. The pivotal trials demonstrating efficacy evaluated patients meeting full diagnostic criteria for insomnia disorder, not transient sleep difficulties.